Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : GSK | McNeil AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 04, 2015
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : GSK | McNeil AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Recipient : University of Utah
Deal Size : Inapplicable
Deal Type : Inapplicable
OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 13, 2014
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Recipient : University of Utah
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2014
Lead Product(s) : Paracetamol
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Long-Acting Acetaminophen in Postoperative Dental Pain
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2013
Lead Product(s) : Paracetamol
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : California Allergy and Asthma Medical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Bronchodilation Effects of Cetirizine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2013
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : California Allergy and Asthma Medical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : McNeil AB | GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 15, 2011
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : McNeil AB | GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2010
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
